TY - JOUR
T1 - Acute myelogenous leukemia and its microenvironment
T2 - A Molecular conversation
AU - Ghiaur, Gabriel
AU - Wroblewski, Mark
AU - Loges, Sonja
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Survival of patients with acute myelogenous leukemia (AML) depends on our ability to prevent relapse in patients that achieved complete remission after intensive chemotherapy. While studies focusing on the malignant clone brought many advances in understanding AML biology and chemoresistance, little improvement has been made in eliminating the last bastion of malignant cells, the minimal residual disease (MRD). Inspired by Sir Paget's "soil and seed" hypothesis, it is becoming more clear that there is constant feedback between the malignant clone and the leukemic microenvironment. This "molecular conversation" dictates AML behavior and holds the key to eliminating MRD. Here we review recent advances in our understanding of how leukemia cells modify their microenvironment and how these changes reinforce AML homeostasis. In addition, we outline current clinical and preclinical efforts to disrupt these interactions and to therapeutically target MRD.
AB - Survival of patients with acute myelogenous leukemia (AML) depends on our ability to prevent relapse in patients that achieved complete remission after intensive chemotherapy. While studies focusing on the malignant clone brought many advances in understanding AML biology and chemoresistance, little improvement has been made in eliminating the last bastion of malignant cells, the minimal residual disease (MRD). Inspired by Sir Paget's "soil and seed" hypothesis, it is becoming more clear that there is constant feedback between the malignant clone and the leukemic microenvironment. This "molecular conversation" dictates AML behavior and holds the key to eliminating MRD. Here we review recent advances in our understanding of how leukemia cells modify their microenvironment and how these changes reinforce AML homeostasis. In addition, we outline current clinical and preclinical efforts to disrupt these interactions and to therapeutically target MRD.
UR - http://www.scopus.com/inward/record.url?scp=84937434287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937434287&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2015.03.003
DO - 10.1053/j.seminhematol.2015.03.003
M3 - Review article
C2 - 26111467
AN - SCOPUS:84937434287
SN - 0037-1963
VL - 52
SP - 200
EP - 206
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - 3
ER -